Eurizon SLJ Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$455K Hold
1,808
0.17% 69
2026
Q1
$393K Sell
1,808
-1,544
-46% -$342K 0.19% 62
2025
Q4
$766K Buy
+3,352
New +$764K 0.3% 51

Other funds holding ABBV

Eurizon SLJ Capital's ABBV Position: Q2 2026 in Review

Eurizon SLJ Capital held its AbbVie (ABBV) position steady in Q2 2026 at 1,808 shares worth $455K. The position accounts for 0.17% of the portfolio, ranked #69.

Eurizon SLJ Capital first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. The position peaked at $766K in Q4 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Eurizon SLJ Capital held 1,808 shares of AbbVie worth $455K as of Q2 2026.
  • Eurizon SLJ Capital left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.17% of Eurizon SLJ Capital's portfolio in Q2 2026, its #69 holding.
  • Eurizon SLJ Capital first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • Eurizon SLJ Capital's AbbVie position peaked at $766K in Q4 2025.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Eurizon SLJ Capital's 13F filing for Q2 2026, filed 3 Aug 2026.